Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis
Author:
Funder
Vetenskapsrådet
Hjärt-lungfonden
Publisher
Elsevier BV
Reference19 articles.
1. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis;Zhang;J Thorac Dis,2015
2. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis;Agyeman;Ann Clin Microbiol Antimicrob,2016
3. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis;Jaspard;France. Emerg Infect Dis.,2020
4. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis;Lan;Lancet Respir Med,2020
5. The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis;Hasan;Clin Infect Dis,2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3